Advanced parenchymal lung disease: Quality of life and palliative care

Mount Sinai Journal of Medicine

Volumn 76, Issue 1, 2009, Pages 63-70

  Gilbert, Christopher R ^a   Smith, Cecilia M ^b  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b READING HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Advanced interstitial lung disease; Dyspnea; End of life care; Hospice; Palliative care; Quality of life

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; CODEINE; CORTICOSTEROID; DEXTROMETHORPHAN; LORAZEPAM; MORPHINE; NARCOTIC AGENT; OPIATE; SEROTONIN UPTAKE INHIBITOR; THALIDOMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; VASODILATOR AGENT;

ADVANCED LUNG DISEASE; ARTICLE; ASTHMA; ATTITUDE TO ILLNESS; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COUGHING; DISEASE CONTROL; DOCTOR PATIENT RELATION; DRUG EFFICACY; DYSPNEA; FUNCTIONAL STATUS; HOME CARE; HOSPICE CARE; HUMAN; HYPOXEMIA; LUNG DISEASE; LUNG FIBROSIS; LUNG INSUFFICIENCY; OXYGEN THERAPY; PALLIATIVE THERAPY; PANIC; PATIENT GUIDANCE; PATIENT SATISFACTION; PULMONARY HYPERTENSION; PULMONARY REHABILITATION; QUALITY OF LIFE; RESPIRATION DEPRESSION; SLEEP DEPRIVATION; SOCIAL INTERACTION; SOCIAL SUPPORT; TERMINAL CARE; TREATMENT RESPONSE; METHODOLOGY;

HUMANS; LUNG DISEASES; PALLIATIVE CARE; QUALITY OF LIFE; TERMINAL CARE;

EID: 65349085389     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20091     Document Type: Article

References (63)

1. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000; 161: 646-664.
2. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-133.
3. Johnson MA, Kwan S, Snell NJ, et al. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44: 280-288.
4. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144: 291-296.
5. Unilateral lung transplantation for pulmonary fibrosis. Toronto Lung Transplant Group. N Engl J Med 1986; 314: 1140-1145.
6. Thabut G, Mal H, Castier Y, et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg 2003; 126: 469-475.
7. Selman M. From anti-inflammatory drugs through antifibrotic agents to lung transplantation: a long road of research, clinical attempts, and failures in the treatment of idiopathic pulmonary fibrosis. Chest 2002; 122: 759-761.
8. Selecky PA, Eliasson CAH, Hall RI, et al. Palliative and end-of-life care for patients with cardiopulmonary diseases: American College of Chest Physicians position statement. Chest 2005; 128: 3599-3610.
9. Constitution of the World Health Organization. Chronicle World Health Org 1947; 1: 29-43.
10. Flanagan JC. A research approach to improving our quality of life. Am Psychol 1978; 33: 138-147.
11. Swigris JJ, Kuschner WG, Jacobs SS, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax 2005; 60: 588-594.
12. Baddini Martinez JA, Martinez TY, Lovetro Galhardo FP, de Castro Pereira CA. Dyspnea scales as a measure of health-related quality of life in patients with idiopathic pulmonary fibrosis. Med Sci Monit 2002; 8: CR405-CR410.
13. Swigris J, Stewart A, Gould M, Wilson S. Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes 2005; 3: 61.
14. Vries JD, Kessels BLJ, Drent M. Quality of life of idiopathic pulmonary fibrosis patients. Eur Respir J 2001; 17: 954-961.
15. Martinez TY, Pereira CAC, dos Santos ML, et al. Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with idiopathic pulmonary fibrosis. Chest 2000; 117: 1627-1632.
16. Jastrzebski D, Kozielski J, Banas A, et al. Quality of life during one-year observation of patients with idiopathic pulmonary fibrosis awaiting lung transplantation. J Physiol Pharmacol 2005; 56(suppl 4): 99-105.
17. Swigris JJ, Gould MK, Wilson SR. Health-related quality of life among patients with idiopathic pulmonary fibrosis. Chest 2005; 127: 284-294.
18. Nishiyama O, Taniguchi H, Kondoh Y, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor? Respir Med 2005; 99: 408-414.
19. De Vries J, Seebregts A, Drent M. Assessing health status and quality of life in idiopathic pulmonary fibrosis: which measure should be used? Respir Med 2000; 94: 273-278.
20. De Vries J, Drent M. Quality of life and health status in interstitial lung diseases. Curr Opin Pulm Med 2006; 12: 354-358.
21. Reynolds HY. Diagnostic and management strategies for diffuse interstitial lung disease. Chest 1998; 113: 192-202.
22. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142(pt 1): 963-967.
23. Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. a randomized prospective study. Am J Respir Crit Care Med 1998; 158: 220-225.
24. Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis. Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 2000; 161: 1172-1178.
25. Webb M, Moody LE, Mason LA. Dyspnea assessment and management in hospice patients with pulmonary disorders. Am J Hosp Palliat Med 2000; 17: 259-264.
26. Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003; 327: 523-528.
27. Jennings AL, Davies AN, Higgins JPT, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002; 57: 939-944.
28. Ajemian I. Palliative management of dyspnea. J Palliat Care 1991; 7: 44-45.
29. Dudgeon DJ, Rosenthal S. Management of dyspnea and cough in patients with cancer. Pain Palliat Care 1996; 10: 157-171.
30. Bruera E, MacEachern T, Ripamonti C, Hanson J. Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med 1993; 119: 906-907.
31. Smoller JW, Pollack MH, Otto MW, et al. Panic anxiety, dyspnea, and respiratory disease. Theoretical and clinical considerations. Am J Respir Crit Care Med 1996; 154: 6-17.
32. Periyakoil VS, Skultety K, Sheikh J. Panic, anxiety, and chronic dyspnea. J Palliat Med 2005; 8: 453-459.
33. Brown KK. Chronic cough due to chronic interstitial pulmonary diseases: ACCP evidence-based clinical practice guidelines. Chest 2006; 129(suppl): 180S-185S.
34. Horton MR, Danoff SK, Lechtzin N. Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis. Thorax 2008; 63: 749.
35. Madison JM, Irwin RS. Chronic cough in adults with interstitial lung disease. Curr Opin Pulm Med 2005; 11: 412-416.
36. Emtner M, Porszasz J, Burns M, et al. Benefits of supplemental oxygen in exercise training in nonhypoxemic chronic obstructive pulmonary disease patients. Am J Respir Crit Care Med 2003; 168: 1034-1042.
37. Tomioka H, Imanaka K, Hashimoto K, Iwasaki H. Health-related quality of life in patients with idiopathic pulmonary fibrosis-cross-sectional and longitudinal study. Intern Med 2007; 46: 1533-1542.
38. Sant'Anna CA, Stelmach R, Zanetti Feltrin MI, et al. Evaluation of health-related quality of life in low-income patients with COPD receiving long-term oxygen therapy. Chest 2003; 123: 136-141.
39. Reisfield GM, Wilson GR. The cost of breathing: an economic analysis of the patient cost of home oxygen therapy. Am J Hosp Palliat Med 2004; 21: 348-352.
40. Traveling with oxygen. Available at: http://www.your lunghealth.org/ healthy_living/articles/traveling/index.cfm. Accessed June 2008.
41. Gendreau MA, DeJohn C. Responding to medical events during commercial airline flights. N Engl J Med 2002; 346: 1067-1073.
42. Martin SE, Bradley JM, Buick JB, et al. Flight assessment in patients with respiratory disease: hypoxic challenge testing vs. predictive equations. QJM 2007; 100: 361-367.
43. Christensen CC, Ryg MS, Kare Refvem O, Henning Skjonsberg O. Effect of hypobaric hypoxia on blood gases in patients with restrictive lung disease. Eur Respir J 2002; 20: 300-305.
44. Seccombe LM, Kelly PT, Wong CK, et al. Effect of simulated commercial flight on oxygenation in patients with interstitial lung disease and chronic obstructive pulmonary disease. Thorax 2004; 59: 966-970.
45. Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest 2007; 131(suppl): 4S-42S.
46. Naji NA, Connor MC, Donnelly SC, McDonnell TJ. Effectiveness of pulmonary rehabilitation in restrictive lung disease. J Cardiopulm Rehabil 2006; 26: 237-243.
47. Jastrzebski D, Gumola A, Gawlik R, Kozielski J. Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. J Physiol Pharmacol 2006; 57(suppl 4): 139-148.
48. Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128: 2393-2399.
49. Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007; 131: 897-899.
50. Clark M, Cooper B, Singh S, et al. A survey of nocturnal hypoxaemia and health related quality of life in patients with cryptogenic fibrosing alveolitis. Thorax 2001; 56: 482-486.
51. Perez-Padilla R, West P, Lertzman M, Kryger MH. Breathing during sleep in patients with interstitial lung disease. Am Rev Respir Dis 1985; 132: 224-229.
52. Statement on home care for patients with respiratory disorders. Am J Respir Crit Care Med 2005; 171: 1443-1464.
53. Hansen-Flaschen J. Chronic obstructive pulmonary disease: the last year of life. Respir Care 2004; 49: 90-97 discussion 97-98.
54. Hughes SL, Weaver FM, Giobbie-Hurder A, et al. Effectiveness of team-managed home-based primary care: a randomized multicenter trial. JAMA 2000; 284: 2877-2885.
55. Bourbeau J, Julien M, Maltais F, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 2003; 163: 585-591.
56. Fox E, Landrum-McNiff K, Zhong Z, et al. Evaluation of prognostic criteria for determining hospice eligibility in patients with advanced lung, heart, or liver disease. JAMA 1999; 282: 1638-1645.
57. Emanuel LL, Barry MJ, Stoeckle JD, et al. Advance directives for medical care-a case for greater use. N Engl J Med 1991; 324: 889-895.
58. Stapleton RD, Nielsen EL, Engelberg RA, et al. Association of depression and life-sustaining treatment preferences in patients with COPD. Chest 2005; 127: 328-334.
59. Rosenfeld KE, Wenger NS, Phillips RS, et al. Factors associated with change in resuscitation preference of seriously ill patients. The SUPPORT Investigators. Arch Intern Med 1996; 156: 1558-1564.
60. Blivet S, Philit F, Sab JM, et al. Outcome of patients with idiopathic pulmonary fibrosis admitted to the ICU for respiratory failure. Chest 2001; 120: 209-212.
61. Davidson P, Introna K, Daly J, et al. Cardiorespiratory nurses' perceptions of palliative care in nonmalignant disease: data for the development of clinical practice. Am J Crit Care 2003; 12: 47-53.
62. Abrahm JL, Hansen-Flaschen J. Hospice care for patients with advanced lung disease. Chest 2002; 121: 220-229.
63. Nathan SD. Lung transplantation: disease-specific considerations for referral. Chest 2005; 127: 1006-1016.